GLENMARK PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLENMARK PHARMACEUTICALS have decreased by -5.86% YoY .
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has decreased by Negative YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLENMARK PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532296|NSE : GLENMARK]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr | ₹9,865 Cr |
| Expenses | ₹9,948 Cr | ₹9,985 Cr | ₹8,860 Cr | ₹8,943 Cr | ₹8,280 Cr |
| Operating Profit (Excl OI) | ₹1,635 Cr | ₹2,320 Cr | ₹2,084 Cr | ₹1,698 Cr | ₹1,586 Cr |
| Other Income | ₹289 Cr | ₹167 Cr | ₹50 Cr | ₹160 Cr | ₹208 Cr |
| Interest | ₹349 Cr | ₹298 Cr | ₹353 Cr | ₹377 Cr | ₹335 Cr |
| Depreciation | ₹569 Cr | ₹487 Cr | ₹444 Cr | ₹417 Cr | ₹326 Cr |
| Profit Before Tax | ₹240 Cr | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr | ₹1,301 Cr |
| Profit After Tax | ₹-90 Cr | ₹994 Cr | ₹970 Cr | ₹776 Cr | ₹925 Cr |
| Consolidated Net Profit | ₹297 Cr | ₹942 Cr | ₹970 Cr | ₹776 Cr | ₹925 Cr |
| Earnings Per Share (Rs) | ₹-53.21 | ₹10.53 | ₹33.37 | ₹34.38 | ₹27.50 |
| PAT Margin (%) | -6.61 | -0.32 | 3.57 | 3.84 | 7.29 |
| ROE(%) | -21.18 | -0.97 | 12.33 | 14.81 | 13.32 |
| ROCE(%) | 4.88 | 4.43 | 14.19 | 15.30 | 14.04 |
| Total Debt/Equity(x) | 0.13 | 0.46 | 0.40 | 0.67 | 0.80 |
Key Financials |
||
| Market Cap | : | ₹ 40,810.4 Cr |
| Revenue (TTM) | : | ₹ 13,128.5 Cr |
| Net Profit(TTM) | : | ₹ -195.9 Cr |
| EPS (TTM) | : | ₹ -6.9 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 3.7% | 5% | 40.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.3% | 3.1% | 13.4% |
| DIVIS LABORATORIES | 3.5% | 11% | 63.5% |
| CIPLA | 1.6% | 2.7% | 11.6% |
| TORRENT PHARMACEUTICALS | 4.1% | 4.4% | 24.7% |
| DR REDDYS LABORATORIES | 6.8% | 11.3% | 3.1% |
| MANKIND PHARMA | 6.1% | 8.9% | 14% |
| ZYDUS LIFESCIENCES | 3% | 4.2% | -8% |
| LUPIN | 1.7% | 5.2% | 28.7% |
GLENMARK PHARMACEUTICALS Revenues
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -5.86 % |
| 5 Yr CAGR | 4.09 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹11,583 Cr | -5.86 | |
| Mar2023 | ₹12,305 Cr | 12.44 | |
| Mar2022 | ₹10,944 Cr | 2.85 | |
| Mar2021 | ₹10,641 Cr | 7.86 | |
| Mar2020 | ₹9,865 Cr | - | |
GLENMARK PHARMACEUTICALS Operating Profit
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -29.53 % |
| 5 Yr CAGR | 0.77 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,635 Cr | -29.53 | |
| Mar2023 | ₹2,320 Cr | 11.32 | |
| Mar2022 | ₹2,084 Cr | 22.75 | |
| Mar2021 | ₹1,698 Cr | 7.08 | |
| Mar2020 | ₹1,586 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -25.13 % |
| 5 Yr CAGR | -3.18 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 14.12% | -25.13 | |
| Mar2023 | 18.86% | -1.00 | |
| Mar2022 | 19.05% | 19.36 | |
| Mar2021 | 15.96% | -0.68 | |
| Mar2020 | 16.07% | - | |
GLENMARK PHARMACEUTICALS Profit After Tax
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -68.44 % |
| 5 Yr CAGR | -24.71 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹297 Cr | -68.44 | |
| Mar2023 | ₹942 Cr | -2.92 | |
| Mar2022 | ₹970 Cr | 25.01 | |
| Mar2021 | ₹776 Cr | -16.11 | |
| Mar2020 | ₹925 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | -6.61 % | Negative | |
| Mar2023 | -0.32 % | Negative | |
| Mar2022 | 3.57 % | -7.03 | |
| Mar2021 | 3.84 % | -47.33 | |
| Mar2020 | 7.29 % | - | |
GLENMARK PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹-53 | Negative | |
| Mar2023 | ₹11 | -68.44 | |
| Mar2022 | ₹33 | -2.94 | |
| Mar2021 | ₹34 | 25.02 | |
| Mar2020 | ₹28 | - | |
GLENMARK PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 10.16 % |
| 5 Yr CAGR | -23.22 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 4.88% | 10.16 | |
| Mar2023 | 4.43% | -68.78 | |
| Mar2022 | 14.19% | -7.25 | |
| Mar2021 | 15.3% | 8.97 | |
| Mar2020 | 14.04% | - | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,446.2 |
| Current MarketCap | : | ₹ 40,810.4 Cr |
| Updated EOD on | : | May 15,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 3.7% |
5% |
40.9% |
| SENSEX | 2.7% |
11.8% |
14% |
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE 400 MIDSMALLCAP INDEX | 6.2% | 12.9% | 11% |
| BSE 150 MIDCAP INDEX | 5.9% | 12.8% | 12.8% |
| BSE MIDCAP | 5.9% | 12.8% | 9.7% |
| BSE MOMENTUM INDEX | 5% | 13.9% | 6.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 6.6% | 16.8% | 6.3% |
| NIFTY 500 EQUAL WEIGHT | 6.5% | 13% | NA |
| NIFTY MIDSMALLCAP 400 | 6.2% | 13.4% | 11.7% |
| NIFTY MIDCAP 100 | 6.2% | 14% | 15.1% |
| NIFTY SMALLCAP250 MOMENTUM QUALITY 100 INDEX | 6.1% | 11.9% | -1% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS Financials
How the annual revenues of GLENMARK PHARMACEUTICALS have changed ?
The Revenues of GLENMARK PHARMACEUTICALS have decreased by -5.86% YoY .
How the Earnings per Share (EPS) of GLENMARK PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has decreased by Negative YoY .
Check out Intrinsic Value of Peers of GLENMARK PHARMACEUTICALS
Compare Stock Analytics of Peers of GLENMARK PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
